What to eat while on treatment Your appetite will decrease significantly on GLP-1 medications
However, the potential for delaying or preventing the progression of T2DM in patients treated with GIP and GLP-1 remains uncertain, as there is currently no definitive evidence from human studies demonstrating that enhanced incretin activity directly affects -cell mass or alters the progressive loss of insulin secretory capacity in humans
This is where the story becomes an investment thesis
81% women, average age 56, and BMI of 40
Monthly clinician check-in adjustments as needed Simple refills ships with a few clicks in your Remedy dashboard Pause, adjust, or cancel anytime Unlimited video calls & messaging between check-ins Take 90 seconds 100% private free Answer a few questions
In the self-insured market, the company changed the prior authorization requirements to require that patients participate in a weight loss program and also required that patients have an in-person relationship with their prescriber